Is Atrium Therapeutics, Inc. RNA stock halal to invest in?

No, as of August 2026, Atrium Therapeutics, Inc. stock (RNA) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. To qualify as halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. Atrium Therapeutics, Inc. currently does not meet the threshold for the interest-bearing investments screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of Atrium Therapeutics, Inc. and discover Shariah compliant alternatives among the halal stocks in the Tabadulat app.

How often is Atrium Therapeutics, Inc. RNA reviewed for Shariah compliance?

Tabadulat reviews Atrium Therapeutics, Inc. RNA for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Atrium Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Non Permissible Income criteria?

Yes, as of August 2026, Atrium Therapeutics, Inc. stock (RNA) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Atrium Therapeutics, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Interest Bearing Investments criteria?

No, as of August 2026, Atrium Therapeutics, Inc. stock (RNA) does not pass the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. Atrium Therapeutics, Inc.'s interest-bearing investments currently exceed this 30% limit, meaning too large a share of the company's value derives from riba-based instruments for the stock to qualify as halal on this criterion. The ratio moves with both the balance sheet and the share price, and is reassessed monthly.

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, Atrium Therapeutics, Inc. stock (RNA) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Atrium Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Atrium Therapeutics, Inc. RNA stock?

Atrium Therapeutics, Inc. (RNA) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a halal investment. If Atrium Therapeutics, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Preference Share screen?

Yes, as of August 2026, Atrium Therapeutics, Inc. stock (RNA) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Atrium Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Avidity Biosciences, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

RNA

About

Avidity Biosciences, Inc.

RNA

Avidity Biosciences Inc. is a biotechnology company focused on the development of innovative therapies for unmet medical needs. The primary aim of Avidity is to harness its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform to create transformative healthcare solutions. This platform combines antibodies and oligonucleotides to precisely target and deliver therapeutic payloads to specific diseased cells, potentially advancing treatments for a range of genetic disorders. The company's research primarily impacts sectors such as rare disease treatment and genetic medicine, where precision and efficacy are critical. By leveraging its unique technology, Avidity Biosciences plays a significant role in the biotechnology landscape, fostering advancements that seek to alter the genetic disease treatment paradigm and improve patient outcomes globally.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

391

Website:

https://www.aviditybiosciences.com

RNA

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Avidity Biosciences, Inc.

About

Avidity Biosciences, Inc.

RNA

Frequently asked questions

Is Atrium Therapeutics, Inc. RNA stock halal to invest in?

How often is Atrium Therapeutics, Inc. RNA reviewed for Shariah compliance?

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Non Permissible Income criteria?

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Interest Bearing Investments criteria?

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for Atrium Therapeutics, Inc. RNA stock?

Does Atrium Therapeutics, Inc. RNA pass the AAOIFI Preference Share screen?

Can I buy Atrium Therapeutics (RNA) stock on Tabadulat?

Open your account.

Deposit.

Screen.